文献速递白血病造血干细胞移植与细胞治疗

儿童急性髓系白血病造血干细胞移植:AML SCT-BFM 2007 试验结果

Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.
PubMed 文献 · Leukemia · 2019-10-02

AML SCT-BFM 2007 是德国首个符合欧盟临床试验指令的儿童急性髓系白血病造血干细胞移植试验,旨在标准化德国、奥地利和捷克各中心的儿童移植。高危但早期反应良好并达首次完全缓解(CR-1)及首次复发后达CR-2的患儿接受清髓性预处理后行配型供者移植,4年EFS和OS分别为61%和70%,复发累积发生率为22%,TRM为15%且与年龄相关。原发反应差或复发患儿接受早期减低强度预处理移植及预防性供者淋巴细胞输注,4年EFS和OS分别为49%和53%。

要点

  • 高危但早期反应良好达CR-1或CR-2患儿清髓移植后4年EFS 61%、OS 70%。
  • 清髓移植TRM为15%,<12岁儿童9%,较大儿童及青少年31%。
  • 原发反应差患儿早期RIC移植加预防性DLI可使EFS达46%。

核心结论

  • 儿童高危AML达CR-1或CR-2后行清髓性配型供者移植,4年EFS为61%、OS为70%。
  • 原发反应差或复发患儿接受早期RIC移植联合预防性DLI,4年EFS为49%、OS为53%。
  • 原发反应差患儿中,早期RIC移植后预防性DLI可使超过50%获得长期缓解,EFS为46%(SE 9%)。

研究设计与样本

  • AML SCT-BFM 2007是德国首个符合欧盟临床试验指令的造血干细胞移植试验。
  • 试验旨在标准化德国、奥地利和捷克各中心儿童AML的造血干细胞移植。
  • 高危但早期反应良好达CR-1及首次复发后达CR-2患儿接受清髓性预处理(白消安、环磷酰胺、美法仑)后配型供者移植。
  • 原发反应差或复发患儿接受氟达拉滨、安吖啶和阿糖胞苷减细胞方案后早期RIC移植及预防性供者淋巴细胞输注。

主要发现

  • 清髓移植组4年EFS为61%,OS为70%。
  • 清髓移植组复发累积发生率为22%,TRM为15%。
  • 清髓移植组TRM与年龄相关:<12岁儿童为9%(SE 3%),较大儿童及青少年为31%(SE 9%)。
  • 早期RIC移植组4年EFS为49%,OS为53%。
  • 早期RIC移植组复发累积发生率为38%,TRM为11%。

关键数值与推荐

  • 高危但早期反应良好达CR-1或CR-2患儿:清髓性预处理后配型供者移植。
  • 原发反应差或复发患儿:减细胞方案后早期RIC移植联合预防性DLI。

临床怎么用

  • 高危儿童AML达CR-1且早期反应良好者,可考虑清髓性配型供者移植。
  • 首次复发后达CR-2的儿童AML患者,可考虑清髓性配型供者移植。
  • 原发反应差患儿可考虑早期RIC移植联合预防性DLI以诱导长期缓解。
  • 清髓移植TRM随年龄增加,需关注较大儿童及青少年的移植风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AML SCT-BFM 2007 was the first hematopoietic stem cell transplantation (HCT) trial in Germany to comply with the European Clinical Trials Directive, and aimed to standardize pediatric HCT for acute myeloid leukemia (AML) across centers in Germany, Austria, and the Czech Republic. Children with high-risk features and a good early response achieving a complete first remission (CR-1) and those in CR-2 after a first relapse were stratified to receive HCT from a matched donor after myeloablative conditioning consisting of busulfan, cyclophosphamide, and melphalan. Four-year EFS and OS were 61 and 70%. Cumulative incidence of relapse (CIR) was 22%. TRM was 15% and correlated with age reaching 9% (SE 3%) in children younger than 12 years and 31% (SE 9%) in older children and adolescents. Children with poorly responding primary disease or relapse were allocated to receive early HCT after a cytoreductive regimen with fludarabine, amsacrine, and cytarabine, followed by reduced intensity conditioning and prophylactic donor lymphocyte infusions. Four-year EFS and OS were 49 and 53%. CIR was 38% and TRM 11%. For patients with primary poor response disease, early use of RIC HCT followed by prophylactic DLI can induce long-term remissions in more than 50% (EFS 46% (SE 9%)).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sauer MG, Lang PJ, Albert MH, et al. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2019. PMID: 31578451. doi:10.1038/s41375-019-0584-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。